from The American Heritage® Dictionary of the English Language, 4th Edition

  • n. Either of two proteins, released by macrophages and other cells, that induce the production of interleukin-2 by helper T cells and stimulate the inflammatory response.


inter- + Greek leukos, white; see leuko- + -in.
(American Heritage® Dictionary of the English Language, Fourth Edition)


  • People with the rare, inherited condition, called cryoprin-associated periodic syndrome, or CAPS, have a genetic mutation that causes the body to overproduce a protein called interleukin-1 beta, which leads to inflammation and tissue damage.

    Novartis Seeks New Use for Ilaris

  • The animals suffered an increase in an inflammation-causing chemical called interleukin-1, used by the body to fight infections, and had fewer complex nerve cells that carry signals to the brain from the rest of the body. | Top Stories

  • Aspirin blocks the pyrogen-induced production of prostaglandins, the central nervous system response to COX and the release of interleukin-1.

    Aspirin: effects, poisoning

  • Novartis now aims to market Ilaris to treat gouty arthritis, also known as gout, a disease that is also triggered by overproduction of interleukin-1 beta.

    Novartis Seeks New Use for Ilaris

  • The cytokines, including tumor necrosis factor alpha and interleukin-1, -4, -6, -8, and -10, result in a cascade of events that are highly destructive to lung tissue.

    Forever Young

  • Carnitine can also decrease the production of pro-inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor alpha.

    Forever Young

  • That genetic mutation causes the body to overproduce interleukin-1, a protein tied to the immune system.

    FDA Approves a Novel Novartis Drug

  • Novartis, meanwhile, is also testing Ilaris in juvenile rheumatoid arthritis, diabetes and respiratory disease, all of which it believes are caused in part by interleukin-1.

    FDA Approves a Novel Novartis Drug

  • Dr. Hoffman of UCSD said interleukin-1 is probably tied to a host of inflammatory diseases, but unlike the situation with CAPS, it won't be the sole cause in other disorders.

    FDA Approves a Novel Novartis Drug

  • On August 2, the US Patent and Trademark Office issued XOMA a new patent covering methods of treating certain coronary conditions including myocardial infarction, or heart attack, using XOMA 052 and interleukin-1 beta antibodies with similar binding properties.


Log in or sign up to get involved in the conversation. It's quick and easy.